Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07456878 · ClinicalTrials.gov registry record · Phase 1
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
A Phase 1 study of Pituitary Adenoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT07456878: Recruiting Phase 1 study of Pituitary Adenoma, sponsored by Mayo Clinic.
NCT07456878 is a Phase 1 study of Pituitary Adenoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 5 participants, below the 288-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07456878, a Phase 1 study of Pituitary Adenoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.
Primary Outcome
Percentage of cases where surgical findings and pathology are concordant with \[18F\]FET-PET/MRI imaging
Conditions Studied
Interventions
- DRUG FET-PET/MRI
Study Locations (1)
Florida
- Mayo Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT07456878 shows while recruiting
NCT07456878 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 288-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pituitary Adenoma appearing as the primary indexed condition, and to 1 intervention - of which FET-PET/MRI is the first listed.
NCT07456878 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07456878 about?
NCT07456878 is a clinical study titled "Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas". The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.
What is the current status of trial NCT07456878?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2026-01-08. Estimated completion is 2026-12.
What conditions does trial NCT07456878 study?
This clinical trial studies the following conditions: Pituitary Adenoma.
What interventions are being tested in trial NCT07456878?
The interventions under investigation include: FET-PET/MRI (DRUG).
Who is sponsoring clinical trial NCT07456878?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07456878 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pituitary Adenoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07456878's enrollment target sits among peer trials
5 10th of 9 the lowest of 9 other Pituitary Adenoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pituitary Adenoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
RECRUITING · Phase 4
-
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
RECRUITING
-
DDAVP for Pituitary Adenoma
RECRUITING · NA
-
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RECRUITING · Phase 4
-
Surgical Debulking of Pituitary Adenomas
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI